Amgen (AMGN) Capital Expenditures (2009 - 2026)

Amgen has reported Capital Expenditures for 18 years, with the latest figure at $513.0 million in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 39.02% year-over-year to $513.0 million in Q2 2026; TTM through Jun 2026 was $2.3 billion, a 63.57% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 69.53% from the prior year.
• Capital Expenditures was $513.0 million for Q2 2026 at Amgen, down from $712.0 million in the prior quarter.
• The five-year high for Capital Expenditures was $712.0 million in Q1 2026, with the low at $160.0 million in Q3 2022.
• Average Capital Expenditures over 5 years is $345.9 million, with a median of $305.5 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures slumped 33.88% in 2022, then jumped 81.05% in 2023.
• Over 5 years, Capital Expenditures stood at $340.0 million in 2022, then fell by 26.76% to $249.0 million in 2023, then surged by 49.0% to $371.0 million in 2024, then soared by 73.05% to $642.0 million in 2025, then fell by 20.09% to $513.0 million in 2026.
• The last three Capital Expenditures figures came in at $513.0 million (Q2 2026), $712.0 million (Q1 2026), and $642.0 million (Q4 2025), per Business Quant data.